Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   43206   clinical trials with a EudraCT protocol, of which   7151   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-000350-96
    Sponsor's Protocol Code Number:IM101-863
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-10-22
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2020-000350-96
    A.3Full title of the trial
    A Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment with Subcutaneous Abatacept vs Adalimumab, on Background Methotrexate, in Adults with Early, Seropositive Rheumatoid Arthritis Who Have "Shared Epitope" HLA Class II Risk Alleles and Have an Inadequate Response to Methotrexate
    Studio randomizzato, testa a testa, in singolo cieco, per confrontare la risposta al trattamento con abatacept per via sottocutanea rispetto ad adalimumab sulla terapia di base con metotrexato in adulti affetti da artrite reumatoide sieropositiva precoce che presentano alleli di rischio HLA di classe II per l’“epitopo condiviso” e una risposta inadeguata al metotrexato
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Efficacy of Abatacept vs Adalimumab in Early, Autoantibody positive Rheumatoid Arthritis (RA) and who did not respond well to methotrexate
    Efficacia di abatacept rispetto a adalimumab nell’artrite reumatoide precoce positiva agli autoanticorpi
    A.3.2Name or abbreviated title of the trial where available
    -
    -
    A.4.1Sponsor's protocol code numberIM101-863
    A.5.3WHO Universal Trial Reference Number (UTRN)U1111-1247-1367
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBristol-Myers Squibb International Corporation
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBristol-Myers Squibb International Corporation
    B.5.2Functional name of contact pointGSM-CT
    B.5.3 Address:
    B.5.3.1Street AddressParc de l'Alliance - Avenue de Finlande, 4
    B.5.3.2Town/ cityBraine-l'Alleud
    B.5.3.3Post code1420
    B.5.3.4CountryBelgium
    B.5.6E-mailclinical.trials@bms.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAbatacept
    D.3.2Product code [BMS-188667]
    D.3.4Pharmaceutical form Solution for injection/infusion in pre-filled syringe
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNabatacept
    D.3.9.1CAS number 332348-12-6
    D.3.9.2Current sponsor codeBMS-188667
    D.3.9.4EV Substance CodeSUB20635
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number125
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeFusion protein
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Humira
    D.2.1.1.2Name of the Marketing Authorisation holderAbbVie Deutschland GmbH & Co. KG
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameADALIMUMAB
    D.3.2Product code [-]
    D.3.4Pharmaceutical form Solution for injection in pre-filled syringe
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 331731-18-1
    D.3.9.2Current sponsor code-
    D.3.9.4EV Substance CodeSUB20016
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Rheumatoid Arthritis
    Artrite reumatoide
    E.1.1.1Medical condition in easily understood language
    Rheumatoid Arthritis
    Artrite reumatoide
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 23.1
    E.1.2Level PT
    E.1.2Classification code 10039073
    E.1.2Term Rheumatoid arthritis
    E.1.2System Organ Class 10028395 - Musculoskeletal and connective tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To demonstrate the superiority in efficacy of abatacept compared with adalimumab, both on background MTX, in achieving clinical response (ACR50) at Week 24, in early, seropositive (RF+ and ACPA+) RA patients with the SE HLA Class II risk alleles (ie, SE+).
    Dimostrare la superiorità in termini di efficacia di abatacept rispetto ad adalimumab, entrambi sulla terapia di base con MTX, nel raggiungimento della risposta clinica (ACR50) alla Settimana 24, in pazienti con AR precoce sieropositivi (RF+ e ACPA+) con alleli di rischio HLA di classe II SE (ovvero SE+).
    E.2.2Secondary objectives of the trial
    To compare the efficacy of abatacept with adalimumab, both on background MTX in achieving:
    - clinical remission criteria (DAS28-CRP remission) at Week 24 in early, seropositive RA patients with the SE HLA Class II risk alleles (ie, SE+).
    - clinical response (ACR50) at Week 24 in the whole study population of early, seropositive RA patients.
    - clinical remission criteria (CDAI remission) at Week 24 in early, seropositive RA patients with the SE HLA Class II risk alleles (ie, SE+).
    - improvement in pain at Week 24 in early, seropositive RA patients with the SE HLA Class II risk alleles (ie, SE+).
    To determine: - the efficacy over time by treatment in early, seropositive RA patients (SE+ subset and whole population).
    - the improvement in health-related quality of life over time by treatment in early, seropositive RA patients (SE+ subset and whole population).
    Confrontare l’efficacia di abatacept con adalimumab, entrambi sulla terapia di base con MTX, nel raggiungimento: dei criteri di remissione clinica (DAS28-CRP) alla Settimana 24 in pazienti con AR precoce sieropositivi con alleli di rischio HLA di classe II SE; della risposta clinica (ACR50) alla Settimana 24 nell’intera popolazione dello studio di pazienti con AR precoce sieropositiva; dei criteri di remissione clinica (CDAI) alla Settimana 24 in pazienti con AR precoce sieropositivi con alleli di rischio HLA di classe II SE; del miglioramento del dolore alla Settimana 24 in pazienti con AR precoce sieropositivi con alleli di rischio HLA di classe II SE.
    Determinare: l’efficacia nel tempo in base al trattamento nei pazienti con AR precoce sieropositivi (sottogruppo SE+ e popolazione intera); il miglioramento della qualità della vita correlata alla salute nel tempo in base al trattamento nei pazienti con AR precoce sieropositivi (sottogruppo SE+ e popolazione intera).
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Females, ages = 18 years or local age of majority.
    - Males, ages = 18 years or local age of majority.
    - Participants have early RA, defined as symptoms of RA that started =12 months prior to screening and satisfied the ACR/EULAR 2010 criteria for the classification of RA at some point during the 12-month period.
    - Participants will have the HLA-DRB1 alleles genotyped during screening and will be identified as carrying at least 1 copy of the SE alleles or not. No greater than 25% of randomized participants may be SE negative.
    - Participants must be naive to any targeted (biologic or nonbiologic) DMARDs, conventional synthetic DMARDs other than MTX, investigational therapies for RA.
    - Participants must have been treated with MTX for at least 12 weeks, with a stable dose of oral or parenteral MTX for at least 4 weeks prior to randomization.
    - Participants have an anti-CCP-2 test that is > 3× ULN and are positive for RF according to central lab testing during screening.
    - Participants must have at least a DAS28-CRP = 3.2 at screening.
    - Participants must have currently at least 3 tender and at least 3 swollen joints (excluding distal interphalangeals) at screening and at randomization.
    - Aritrite Reumatoide (AR) precoce, ovvero con sintomi di AR iniziati =12 mesi prima dello screening e che hanno soddisfatto i criteri dell’ American College of Rheumatology/European League Against Rheumatism (ACR / EULAR) 2010 per la classificazione della AR ad un certo punto durante i 12 mesi.
    - “naive” a qualsiasi farmaco antireumatico modificante la malattia (DMARDs) mirato (biologico o non biologico), DMARD sintetici convenzionali diversi da MTX, terapie sperimentali per AR.
    - I partecipanti devono essere stati trattati con MTX per almeno 12 settimane,
    con una dose stabile di MTX orale o parenterale per almeno 4 settimane prima della randomizzazione.
    - test Anti-cyclic citrullinated peptide-2 (anti-CCP-2) che è> 3 × il limite superiore della norma e positività per il Fattore Reumatoide (RF) in base ai test di laboratorio centrali durante lo screening.
    - un punteggio di attività della malattia conteggio di 28 articolazioni calcolato utilizzando la proteina C-reattiva (DAS28-CRP) almeno = 3,2 allo screening.
    - almeno 3 articolazioni fragili e 3 gonfieal momento dello screening e alla randomizzazione.
    E.4Principal exclusion criteria
    - Women who are breastfeeding.
    - Participants with autoimmune disease other than RA or currently active fibromyalgia.
    - Prior history of or current inflammatory joint disease other than RA.
    - Participants at risk for TB infection.
    - Participants with recent acute infection. In the case of prior SARS-CoV-2 infection within 30 days prior to enrollment, symptoms must have completely resolved with no clinically significant sequelae that would indicate a higher risk of participation in the study.
    - Participants with history of primary immunodeficiency.
    - Participants who have received any live vaccines within 3 months of the study drug administration.
    - Participants who have received live attenuated or replicationcompetent vector SARS-CoV-2 vaccines within 3 months of study enrollment.
    - Participants for whom 5 or more joints cannot be assessed for tenderness or swelling (ie, due to surgery, fusion, amputation, etc).
    - Participants who have had previous exposure to abatacept or adalimumab.
    - Participants who have received an IM, IV, or intra-articular administration of a corticosteroid within 4 weeks prior to randomization.
    - Hepatitis B surface antigen (HBsAg)-positive, or hepatitis B core antibody (HBcAb) positive participants with detectable hepatitis B viral deoxyribonucleic acid (DNA).
    - Hepatitis C antibody (HcAb)-positive participants with detectable hepatitis C viral RNA.
    - History of certain types of infections
    Donne in allattamento.
    - malattia autoimmune diversa dall'artrite reumatoide ( ad esempio psoriali, lupus sistemico eritematoso [LES], vasculite, spondiloartrite sieronegativa, malattia infiammatoria intestinale, sindrome di Sjogren) o fibromialgia attiva al momento.
    - Anamnesi precedente o malattia infiammatoria articolare in corso diversa dall'artrite reumatoide (ad esempio artrite psoriasica, gotta, artrite reattiva, malattia di Lyme).
    - rischio di infezione da tubercolosi.
    - infezione acuta recente.
    - storia di infezione batterica cronica o ricorrente (ad es.
    Pielonefrite cronica, osteomielite, bronchiectasie)
    - Storia di infezione di una protesi articolare o di un'articolazione artificiale
    - Storia di infezioni fungine sistemiche (come istoplasmosi,
    blastomicosi o coccidiomicosi)
    - storia di immunodeficienza primaria.
    - Evidenze cliniche in corso o storia di una malattia demielinizzante
    - 5 o più articolazioni non possono essere valutate per fragilità o gonfiore
    E.5 End points
    E.5.1Primary end point(s)
    Proportion of SE+ participants meeting ACR50 response at Week 24
    Percentuale di partecipanti SE+ che soddisfano la risposta ACR50 alla Settimana 24
    E.5.1.1Timepoint(s) of evaluation of this end point
    At Week 24
    Alla settimana 24
    E.5.2Secondary end point(s)
    1. Proportion of SE+ participants achieving DAS28-CRP remission (DAS28-CRP < 2.6) at Week 24
    2. Proportion of whole study population participants meeting ACR50 response at Week 24
    3. Proportion of SE+ participants achieving CDAI remission (CDAI = 2.8) at Week 24
    4. Mean change from baseline in SE+ participant-reported pain (VAS) at Week 24
    5. Proportion of SE+ subset and whole population achieving ACR20/50/70 responses, DAS remission, CDAI remission, SDAI remission over the SBTP and OLTP; mean changes from baseline in DAS28-CRP, CDAI, SDAI over the SBTP and OLTP; mean changes from baseline in the 7 ACR core components over the SBTP and OLTP
    6. Mean change from baseline in SF-36 in SE+ subset and whole population at Week 24 and Week 104 (4 physical and 4 mental subscales and the physical component and mental component summary)
    1. Percentuale di partecipanti SE+ che raggiungono la remissione DAS28-CRP (DAS28-CRP <2,6) alla Settimana 24
    2. Percentuale di partecipanti dell’intera popolazione dello studio che soddisfa la risposta ACR50 alla Settimana 24
    3. Percentuale di partecipanti SE+ che raggiunge la remissione CDAI (CDAI =2,8) alla Settimana 24
    4. Variazione media rispetto al basale del dolore riferito dal partecipante SE+ (VAS) alla Settimana 24
    5. Percentuale del sottogruppo SE+ e della popolazione intera che ha ottenuto risposte ACR20/50/70, remissione DAS, remissione CDAI, remissione SDAI rispetto a SBTP e OLTP; variazioni medie rispetto al basale in DAS28-CRP, CDAI, SDAI rispetto a SBTP e OLTP; variazioni medie rispetto al basale nei 7 componenti principali ACR rispetto a SBTP e OLTP
    6. Variazione media rispetto al basale nel Questionario sulla salute in forma breve a 36 voci (SF-36) nel sottogruppo SE+ e nell’intera popolazione alla Settimana 24 e alla Settimana 104 (4 sottoscale fisiche e 4 mentali e nella sintesi della componente fisica e della componente mentale)
    E.5.2.1Timepoint(s) of evaluation of this end point
    1-4. At Week 24
    5. Over the SBTP and OLTP
    6. At Week 24 and Week 104
    1-4. Alla settimana 24
    5. rispetto a SBTP e OLTP
    6. Alla settimana 24 e alla settimana 104
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind Yes
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA27
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Czechia
    France
    Germany
    Italy
    Japan
    Mexico
    Netherlands
    Poland
    Spain
    Sweden
    Switzerland
    Taiwan
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of trial is defined as last visit for the last participant.
    La conclusione della sperimentazione è definita come l’ultima visita dell’ultimo partecipante
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days9
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days22
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 340
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 60
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    In situations where consent cannot be given by subjects/participants, their legally acceptable representatives (as per country guidelines) are clearly and fully informed regarding clinical studies in which the partecipant volunteers to partecipate.
    Nelle circostanze in cui il consenso non può essere dato dai soggetti/partecipanti, i loro rappresentanti legali (come da linee guida del paese) vengono informati in modo chiaro e completo sugli studi clinici a cui il partecipante si offre a partecip
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state11
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 192
    F.4.2.2In the whole clinical trial 400
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    At the end of the open-label treatment period, BMS will not continue to provide BMS-supplied study treatment to participants/investigators unless BMS chooses to extend the study. The investigator should ensure that the participant receives appropriate standard of care to treat the condition under study.
    Alla fine del periodo di trattamento in aperto, BMS non continuerà a fornire il trattamento di studio ai partecipanti / sperimentatori a meno che BMS non scelga di estendere lo studio. Lo sperimentatore dovrebbe assicurarsi che il partecipante riceva un adeguato standard di cura per trattare la patologia in studio.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-09-21
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-06-30
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA